135 related articles for article (PubMed ID: 10703765)
1. From the Food and Drug Administration.
Henney JE
JAMA; 2000 Mar; 283(9):1131. PubMed ID: 10703765
[No Abstract] [Full Text] [Related]
2. Arthritis drug approved for polyp prevention blazes trail for other prevention trials.
Smigel K
J Natl Cancer Inst; 2000 Feb; 92(4):297-9. PubMed ID: 10675374
[No Abstract] [Full Text] [Related]
3. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
[TBL] [Abstract][Full Text] [Related]
4. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
5. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
Steinbach G; Lynch PM; Phillips RK; Wallace MH; Hawk E; Gordon GB; Wakabayashi N; Saunders B; Shen Y; Fujimura T; Su LK; Levin B; Godio L; Patterson S; Rodriguez-Bigas MA; Jester SL; King KL; Schumacher M; Abbruzzese J; DuBois RN; Hittelman WN; Zimmerman S; Sherman JW; Kelloff G
N Engl J Med; 2000 Jun; 342(26):1946-52. PubMed ID: 10874062
[TBL] [Abstract][Full Text] [Related]
6. [Effect of celecoxib, a COX-2 inhibitor, in familial adenomatous polyposis].
Wullen B; Mühlhöfer A; Zoller WG
Z Gastroenterol; 2001 Apr; 39(4):335-7. PubMed ID: 11367984
[No Abstract] [Full Text] [Related]
7. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.
Phillips RK; Wallace MH; Lynch PM; Hawk E; Gordon GB; Saunders BP; Wakabayashi N; Shen Y; Zimmerman S; Godio L; Rodrigues-Bigas M; Su LK; Sherman J; Kelloff G; Levin B; Steinbach G;
Gut; 2002 Jun; 50(6):857-60. PubMed ID: 12010890
[TBL] [Abstract][Full Text] [Related]
8. Celecoxib: new indication. Colorectal cancer: no preventive benefit.
Prescrire Int; 2006 Feb; 15(81):13-5. PubMed ID: 16548099
[TBL] [Abstract][Full Text] [Related]
9. From the Food and Drug Administration.
Nightingale SL
JAMA; 1999 Mar; 281(9):786. PubMed ID: 10070983
[No Abstract] [Full Text] [Related]
10. Celecoxib as adjunctive therapy for treatment of colorectal cancer.
North GL
Ann Pharmacother; 2001 Dec; 35(12):1638-43. PubMed ID: 11793634
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase inhibition in cancer--a blind alley or a new therapeutic reality?
Chau I; Cunningham D
N Engl J Med; 2002 Apr; 346(14):1085-7. PubMed ID: 11932478
[No Abstract] [Full Text] [Related]
12. Celecoxib.
O'Rourke ME
Clin J Oncol Nurs; 2000; 4(3):143-4. PubMed ID: 11235255
[No Abstract] [Full Text] [Related]
13. Celecoxib with chemotherapy in colorectal cancer.
Blanke CD
Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):17-21. PubMed ID: 12014863
[TBL] [Abstract][Full Text] [Related]
14. Nonsteroidal anti-inflammatory drugs, coxibs, and cardio-renal physiology: a mechanism-based approach.
FitzGerald GA
Am J Cardiol; 2002 Mar; 89(6A):1D-2D. PubMed ID: 11909554
[No Abstract] [Full Text] [Related]
15. Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis.
Henderson P
JAMA; 2002 Apr; 287(14):1799; author reply 1799-800. PubMed ID: 11939848
[No Abstract] [Full Text] [Related]
16. [Current post-marketing information. Effects and adverse effects of celecoxib].
Schmidt H; Geisslinger G
Pharm Unserer Zeit; 2002; 31(2):180-7. PubMed ID: 11977454
[No Abstract] [Full Text] [Related]
17. Clinical profiles of celecoxib and rofecoxib in the rheumatic diseases.
Gibofsky A
J Hypertens Suppl; 2002 Sep; 20(6):S25-30. PubMed ID: 12683424
[TBL] [Abstract][Full Text] [Related]
18. Arthritis medicines and cardiovascular events--"house of coxibs".
Topol EJ
JAMA; 2005 Jan; 293(3):366-8. PubMed ID: 15623849
[No Abstract] [Full Text] [Related]
19. Balancing the risks and benefits of celecoxib.
Caldwell B; Beasley R; Weatherall M; Metcalfe S
Am J Med; 2007 Jun; 120(6):e17. PubMed ID: 17524734
[No Abstract] [Full Text] [Related]
20. [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
Sheng JQ; Li SR; Yang XY; Zhang YH; Su H; Yu DL; Yan W; Geng HG
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):526-9. PubMed ID: 16681880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
